Skip to main content
OpenTrials
Completed

NCT Number: NCT05656872

Transversus Abdominis Plane Block Versus Ilioinguinal-Iliohypogastric Nerve Block for Postoperative Analgesia Following Open Total Abdominal Hysterectomy

The investigators hypothesised that ultrasound-guided transversus abdominis plane (TAP) block would prolong the time to first rescue nalbuphine within 24 hours compared with ultrasound-guided ilioinguinal-iliohypogastric (IIH) nerve block, by virtue of its broader dermatomal coverage (T10-L1 versus T12-L1) of the Pfannenstiel incision. This hypothesis direction was established before unblinding and data analysis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Faculty of Medicine, Cairo University, Cairo, Cairo Governorate, Egypt

Loading trial locations.

About this study

Aim of the work

the aim of the study is to compare between the analgesic effect of Transversus Abdominis Plane Block and Ilioinguinal-iliohypogastric block following open abdominal hysterectomy Objectives

  • to compare between the analgesic effect of Transversus Abdominis Plane Block and Ilioinguinal-iliohypogastric block For Postoperative Analgesia following open abdominal hysterectomy
  • to measure the incidence of complications following both blocks as hematoma, block failure, infection at injection site

Sample size:

Our primary outcome is the time to first rescue analgesia request. In a previous study, the meantime to first rescue analgesia was 10.58 ± 2.35 hours (6). The investigators calculated a sample size that could detect a mean difference of 20% between both study groups. MedCalc Software version 14 (MedCalc Software bvba, Ostend, Belgium) was used to calculate the sample size.38 patients( 19 patients per group) at least were estimated to have a study power of 80% and an alpha error of 0.05. This number will be increased to 42 patients (21 patients per group) to compensate for possible dropouts.

Sample size calculation was performed guided by the power of 80%, confidence level of 95%.

Statistical analysis:

For data analysis, the Statistical Package for Social Science (SPSS) software, version 23.0 for Microsoft Windows (SPSS Inc., Chicago, IL, USA) was used (version 23.0 was used in place of the registered version 26; no impact on any statistical result). Python (SciPy 1.7) was additionally used for area-under-the-curve computation and Holm-Bonferroni multiplicity correction.

Normality of continuous data was assessed using the Shapiro-Wilk test and graphical inspection. Parametric data are reported as mean (standard deviation) and were compared between groups using the independent samples t test. Non-parametric data are reported as median (interquartile range [range]) and were compared using the Mann-Whitney U test. Categorical data are reported as number (proportion) and were compared using the chi-square test or Fisher exact test as appropriate.

The primary outcome time from end of surgery to first rescue nalbuphine within 24 hours was analysed as a time-to-event outcome using the Kaplan-Meier method with log-rank testing, and Cox proportional hazards regression was used to estimate the hazard ratio with 95% confidence interval. Participants who did not require rescue nalbuphine were censored at 24 hours. This approach replaced the t-test framework implied in the original registration, as Kaplan-Meier survival analysis is the methodologically appropriate method for a time-to-event outcome with censored observations. This change was made before unblinding and before any outcome data were examined.

To address multiple comparisons across the eight postoperative pain assessment time points, cumulative pain burden was calculated for each participant as the area under the numerical rating scale pain score-time curve from 5 minutes to 24 hours using the trapezoidal rule (NRS-AUC₅ₘᵢₙ-₂₄ₕ, in score·hours) and compared between groups using the Mann-Whitney U test. Individual time-point comparisons were considered exploratory and p values were adjusted using the Holm-Bonferroni stepwise correction in place of the Bonferroni post-hoc ANOVA approach registered originally; this substitution is more statistically appropriate as it controls the familywise error rate with greater power. Cohen's d was calculated from group means and standard deviations as a supplementary standardised effect-size measure.

All tests were two-sided with α = 0.05. Exact p values are reported throughout rather than thresholds (e.g., p < 0.05). All 42 randomised participants completed 24-hour follow-up and were included in the analysis (intention-to-treat).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants will be adult patients (35-65 years)
  • ASA I-III
  • Scheduled for elective open TAH

Exclusion criteria

  • Patient refusal
  • BMI > 40 kg·m-²
  • Pregnancy
  • Chronic pain requiring daily analgesics
  • Any known allergy to local anesthetic, nalbuphine, paracetamol, or diclofenac
  • Patients with neurological, psychological disorders or those lacking cooperation
  • Patients with anatomic abnormalities at site of injection, skin lesions or wounds at site of proposed needle insertion.
  • Patients with bleeding disorders defined as (INR >2) and/ or (platelet count <100,000/µL)
  • Patients with hepatic disease e.g. liver cell failure or hepatic malignancy or hepatic enlargement

Treatment and study plan

Transverse Abdominis Plane Block

Procedure

Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer GE Healthcare 12L-RS ultrasound will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(B Braun Contiplex 22G echogenic needle, 80-100 mm) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.

Ilioinguinal-iliohypogastric block

Procedure

Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer GE Healthcare 12L-RS ultrasound will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle( Braun Contiplex 22G echogenic needle, 80-100 mm) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.

Primary outcomes

  1. Time to first rescue nalbuphine within 24 hours

    Time frame: From end of surgery to first rescue dose within 24 hours postoperatively

    Time from end of surgery to first administration of rescue nalbuphine (0.15 mg.kg-¹ intravenously, given when numerical rating scale pain score ≥ 4 at rest after 30 minutes).

Secondary outcomes

  1. Total nalbuphine consumption within 24 hours

    Time frame: Immediate 24 hours post-operative

    Total cumulative dose of rescue nalbuphine (mg) administered to each participant from end of surgery to 24 hours postoperatively.

  2. Numerical Rating Scale (NRS)

    Time frame: 5 minutes, 30 minutes, 2 hours, 4 hours, 8 hours, 12 hours, 18 hours, and 24 hours after arrival in the post-anaesthesia care unit

    Pain intensity at rest measured using the Numerical Rating Scale (NRS, 0-10, where 0 = no pain and 10 = worst imaginable pain).

  3. Intraoperative and postoperative haemodynamics (heart rate and mean arterial pressure)

    Time frame: Baseline, every 10 minutes intraoperatively, immediately after extubation, 5 minutes after extubation, every 10 minutes in PACU for 30 minutes, then at 2, 4, 8, 12, 18, and 24 hours postoperatively

    Heart rate (beats per minute) and mean arterial pressure (mmHg) recorded at baseline (before induction), 1 minute after intubation, every 10 minutes intraoperatively, immediately after extubation, 5 minutes after extubation, and every 10 minutes in the post-anaesthesia care unit for 30 minutes. Postoperative assessments also recorded at 2, 4, 8, 12, 18, and 24 hours.

  4. Incidence of postoperative nausea and vomiting

    Time frame: Immediate 24 hours post-operative

    Incidence of postoperative nausea and vomiting

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

A Comparative Study Between Ultrasound-guided Transversus Abdominis Plane Block Versus Ultrasound-guided Ilioinguinal-Iliohypogastric Nerve Block for Postoperative Analgesia Following Open Total Abdominal Hysterectomy: A Randomised Comparative Trial

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Dec 19, 2022
Registry last updated
Apr 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.